WASP - Jeff - this is the news release on the study -- probably not the detail you were looking for but hte IR contact is listed at the bottom -- I plan on calling him Monday -- I just found this one Friday
Monday April 12, 12:38 pm Eastern Time
Company Press Release
Cystic Acne Study Brings Dramatic
Results
MIDVALE, Utah--(BUISNESS WIRE)--April 12,
1999--Wasatch Pharmaceutical Inc. (OTC BB:WASP - news)
has previously announced clinical trials, and the treatment of acne patients in a clinical setting under
the direction and cooperation of a major pharmaceutical research entity, and approximately 250
physicians.
With several thousand patients having been treated, Wasatch has announced a success rate of 95%
with virtually no side effects. Success is interpreted as total or near total eradication of both cystic
acne and the less serious grades of acne. This product is used topically, and is far superior to
anything now being used by prescription or in the over-the-counter market.
With the success of this therapy, entry into the retail market has been solicited by an independent
distributor representing eighteen hundred pharmacies. In addition, two major retail chains
representing over 30% of the over-the-counter market are accessible through relationships presently
representing Wasatch Pharmaceutical.
The acne market is a $3 Billion market and with a superior product, Wasatch will aggressively
penetrate and control a significant share of this market.
This press release contains forward-looking statements regarding Wasatch Pharmaceutical Inc. and
its future sales-related activities. Actual results could differ materially from those described or implied
in this press release as a result of a number of factors. These include, but are not limited to, the future
growth of these markets, any adverse actions by the company*s partners, competitive products,
other economic factors affecting the company*s markets, the degree of acceptance that new
products achieve, and seasonal changes. Readers are referred to public documents filed by Wasatch
Pharmaceutical, Inc. with the Securities and Exchange Commission which identify important risk
factors that could cause actual results to differ from those contained in any forward-looking
statements.
Contact:
Wasatch Pharmaceutical Inc., Midvale
Gary Heesch, 801/272-1709 |
